000290916 001__ 290916
000290916 005__ 20250514144139.0
000290916 0247_ $$2doi$$a10.1002/ana.27009
000290916 0247_ $$2pmid$$apmid:38860471
000290916 0247_ $$2ISSN$$a0364-5134
000290916 0247_ $$2ISSN$$a1531-8249
000290916 0247_ $$2altmetric$$aaltmetric:164458579
000290916 037__ $$aDKFZ-2024-01250
000290916 041__ $$aEnglish
000290916 082__ $$a610
000290916 1001_ $$00000-0002-5415-6567$$aGrut, Viktor$$b0
000290916 245__ $$aInteractions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
000290916 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2024
000290916 3367_ $$2DRIVER$$aarticle
000290916 3367_ $$2DataCite$$aOutput Types/Journal article
000290916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721029405_17128
000290916 3367_ $$2BibTeX$$aARTICLE
000290916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290916 3367_ $$00$$2EndNote$$aJournal Article
000290916 500__ $$a2024 Aug;96(2):302-305
000290916 520__ $$aSynergistic interactions between human herpesvirus 6A (HHV-6A) and Epstein-Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV-6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV-6A and EBNA-1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV-6A and EBV infections interact in MS development. ANN NEUROL 2024.
000290916 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000290916 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290916 7001_ $$00000-0003-3994-2305$$aBiström, Martin$$b1
000290916 7001_ $$aSalzer, Jonatan$$b2
000290916 7001_ $$00000-0003-4855-0039$$aStridh, Pernilla$$b3
000290916 7001_ $$00000-0001-8677-1815$$aJons, Daniel$$b4
000290916 7001_ $$aGustafsson, Rasmus$$b5
000290916 7001_ $$aHuang, Jesse$$b6
000290916 7001_ $$aBergström, Tomas$$b7
000290916 7001_ $$00000-0002-0867-4726$$aKockum, Ingrid$$b8
000290916 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b9$$udkfz
000290916 7001_ $$aOlsson, Tomas$$b10
000290916 7001_ $$aSundström, Peter$$b11
000290916 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.27009$$gp. ana.27009$$n2$$p302-305$$tAnnals of neurology$$v96$$x0364-5134$$y2024
000290916 8564_ $$uhttps://inrepo02.dkfz.de/record/290916/files/Annals%20of%20Neurology%20-%202024%20-%20Grut%20-%20Interactions%20between%20High%20Seroreactivity%20to%20Human%20Herpes%20Virus%206A%20and%20Epstein%20Barr.pdf
000290916 8564_ $$uhttps://inrepo02.dkfz.de/record/290916/files/Annals%20of%20Neurology%20-%202024%20-%20Grut%20-%20Interactions%20between%20High%20Seroreactivity%20to%20Human%20Herpes%20Virus%206A%20and%20Epstein%20Barr.pdf?subformat=pdfa$$xpdfa
000290916 909CO $$ooai:inrepo02.dkfz.de:290916$$pVDB
000290916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000290916 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000290916 9141_ $$y2024
000290916 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000290916 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-24$$wger
000290916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2022$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000290916 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2022$$d2023-10-24
000290916 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x0
000290916 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x1
000290916 980__ $$ajournal
000290916 980__ $$aVDB
000290916 980__ $$aI:(DE-He78)D320-20160331
000290916 980__ $$aI:(DE-He78)F020-20160331
000290916 980__ $$aUNRESTRICTED